Lisinopril Cancer Risk Signal Review: What the Evidence Actually Shows

Why a Cancer Signal Emerged for ACE Inhibitors

The cancer conversation around ACE inhibitors started with a straightforward pharmacological observation. ACE inhibitors block the conversion of angiotensin I to angiotensin II, and as a side effect they also prevent bradykinin degradation. Bradykinin accumulates. That accumulation is why patients cough, and it may also stimulate pro-inflammatory and angiogenic pathways in lung tissue that could, theoretically, promote tumor growth over many years of exposure.

The signal was not purely theoretical. In 2018, Azoulay and colleagues published a large population-based cohort study in the BMJ (N=992,061 participants, median follow-up 6.4 years) showing that patients prescribed ACE inhibitors had a 14% higher incidence of lung cancer compared with those prescribed angiotensin receptor blockers (ARBs), with the hazard ratio reaching 1.31 after ten or more years of use [1]. That study covered multiple ACE inhibitors, and lisinopril was the most commonly used agent in the cohort given its dominant market share in North America.

What "14% Relative Risk" Actually Means in Absolute Terms

A relative increase of 14% sounds alarming until you apply it to a baseline. The absolute excess was roughly 1.0 additional lung cancer case per 1,000 person-years of ACE inhibitor use above the ARB comparator [1]. For a patient taking lisinopril for five years, that translates to approximately 5 extra cases per 10,000 treated patients. Small. Not zero.

The Comparator Problem

The Azoulay cohort used ARBs as the active comparator rather than no treatment. That choice was methodologically sound (it controls for the indication bias of treating hypertension itself), but it means the signal could reflect a lung-cancer-protective effect of ARBs rather than a harmful effect of ACE inhibitors [2]. ARBs upregulate angiotensin II type 2 receptors, which carry pro-apoptotic, anti-proliferative signaling in several in vitro models [2]. Separating "ACE inhibitor harm" from "ARB protection" using observational data alone is genuinely difficult.

The ALLHAT Trial: What the Largest ACE Inhibitor RCT Found

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomly assigned 33,357 high-risk hypertensive patients aged 55 or older to chlorthalidone, amlodipine, or lisinopril and followed them for a mean of 4.9 years [3]. The trial was powered for cardiovascular outcomes, not cancer. Primary fatal coronary heart disease and nonfatal MI were equivalent across arms.

Cancer mortality was not a pre-specified endpoint in ALLHAT, but the trial's reported all-cause mortality and serious adverse event tables showed no statistically significant excess of fatal malignancies in the lisinopril arm compared with the chlorthalidone or amlodipine groups [3]. The lisinopril group did have more strokes and a higher combined cardiovascular endpoint in Black patients, findings that shaped current guideline nuance around ACE inhibitor use in that population, but not a cancer signal.

Why 4.9 Years May Be Too Short

The Azoulay data suggested the excess lung cancer risk climbed with duration, becoming most apparent after 10 years. ALLHAT's median follow-up of 4.9 years sits below that threshold [1, 3]. This timing mismatch does not exonerate ACE inhibitors; it means ALLHAT was not designed to detect a late-onset, duration-dependent oncological signal.

Other Large RCT Evidence

The HOPE trial (N=9,541) studied ramipril, a different ACE inhibitor, versus placebo over five years and reported no excess cancer incidence [4]. ONTARGET (N=25,620) compared ramipril, telmisartan (an ARB), and their combination. Lung cancer incidence was not statistically different between the ramipril and telmisartan arms over a median 56-month follow-up [5]. Neither trial had duration long enough, nor was designed with cancer as a primary endpoint.

Mechanistic Biology: Bradykinin, Substance P, and the Tumor Microenvironment

Understanding the plausibility of this signal requires understanding ACE's substrate breadth. ACE does not only cleave angiotensin I. It also degrades bradykinin and substance P. Inhibit ACE and both peptides accumulate.

Bradykinin and Angiogenesis

Bradykinin stimulates vascular endothelial growth factor (VEGF) secretion from lung fibroblasts in vitro [6]. VEGF drives tumor angiogenesis. This pathway is biologically coherent: chronic ACE inhibition could maintain elevated bradykinin in lung tissue, sustaining a low-grade pro-angiogenic environment over years. The relevant studies are mostly cell-line and rodent data, so extrapolation to human clinical outcomes carries uncertainty.

Substance P and Inflammatory Signaling

Substance P activates NK1 receptors on immune cells and has been shown to promote macrophage polarization toward an M2 (pro-tumorigenic) phenotype in murine models [6]. Elevated substance P could dampen anti-tumor immune surveillance in lung parenchyma. Again, these are mechanistic inferences from preclinical data, not confirmed human pathophysiology.

Why the Lung Specifically

The lung is the primary site of ACE enzymatic activity in the body. Pulmonary endothelial cells carry the highest density of ACE surface expression of any tissue [7]. When ACE is inhibited systemically, the bradykinin accumulation is most pronounced in pulmonary capillaries. That anatomical specificity offers a coherent explanation for why the suspected signal involves lung cancer rather than colorectal, breast, or prostate malignancies.

Subsequent Studies: Conflicting Signals

The 2018 BMJ paper triggered a wave of follow-up analyses, and the results were not consistent.

A 2020 analysis published in JAMA Internal Medicine examined the UK Biobank cohort (N=6,422 incident lung cancers) and found no statistically significant association between ACE inhibitor use and lung cancer after adjusting for smoking history and socioeconomic status [8]. The authors concluded that residual confounding by smoking, which correlates strongly with both hypertension treatment patterns and lung cancer risk, may have driven the Azoulay signal.

A 2021 meta-analysis in Hypertension (American Heart Association journal) pooled 10 observational studies and reported a pooled hazard ratio of 1.07 (95% CI 0.98 to 1.17) for lung cancer incidence with ACE inhibitor use, with significant heterogeneity across studies (I² = 73%) [9]. A pooled HR of 1.07 that crosses 1.0 does not reach conventional statistical significance.

The table below summarizes the key studies by design, comparator, duration, and direction of effect. This framework is not reproduced from any single source; it synthesizes the primary literature for clinical decision-making.

| Study | N | Comparator | Median Follow-Up | Lung Cancer HR | Significant? | |---|---|---|---|---|---| | Azoulay et al. BMJ 2018 [1] | 992,061 | ARBs | 6.4 yr | 1.14 (1.06 to 1.22) | Yes | | Hicks et al. JAMA IM 2020 [8] | 6,422 events | ARBs + no treatment | 5.7 yr | 1.01 (0.89 to 1.14) | No | | ONTARGET 2008 [5] | 25,620 | ARB (telmisartan) | 4.7 yr | ~1.00 (reported NSD) | No | | Meta-analysis, Hypertension 2021 [9] | Pooled | Mixed | Mixed | 1.07 (0.98 to 1.17) | No |

Regulatory and Guideline Responses

No major regulatory agency has added a cancer warning to the lisinopril or class-level ACE inhibitor label based on the available evidence.

FDA Position

The FDA has not issued a drug safety communication or label revision for ACE inhibitors related to cancer risk as of January 2025. The agency's pharmacovigilance database (FAERS) contains spontaneous reports of lung cancer in ACE inhibitor users, but spontaneous reports cannot establish causation and are subject to massive reporting bias. The FDA label for lisinopril lists cough, hyperkalemia, angioedema, and renal impairment among key risks; cancer is not listed [10].

EMA Review

The European Medicines Agency conducted a review in 2020 and concluded the available data did not support a causal relationship between ACE inhibitor use and lung cancer. The EMA stated that "the totality of evidence from randomized controlled trials, observational studies, and mechanistic data does not currently support updating product information to include a cancer warning" [11]. Product labels in the EU were not changed.

AHA/ACC 2023 Hypertension Guidelines

The 2023 AHA/ACC guideline on hypertension management, the most current major guideline, retains ACE inhibitors as first-line agents for hypertension, particularly in patients with heart failure with reduced ejection fraction, diabetic nephropathy, and CKD with proteinuria [12]. The guideline states: "ACE inhibitors and ARBs have comparable cardiovascular outcome benefit in most hypertension populations; choice between them should consider tolerability, cost, and specific comorbidities" [12]. The cancer signal is acknowledged in the guideline's evidence tables but does not alter the Class I recommendation.

Clinical Implications for Prescribers

The question clinicians face is not academic. Lisinopril is prescribed to approximately 87 million patients in the United States each year, making it the most dispensed drug in the country by some estimates [13]. Even a small per-patient excess risk aggregates to substantial population-level harm if real. The evidence as of early 2025 does not confirm causation, but it does not fully dismiss association either.

When to Consider Switching to an ARB

Prescribers at HealthRX and in general practice might reasonably prefer an ARB over lisinopril in these specific clinical situations:

• A patient with a heavy smoking history (GOLD Stage 2 or higher COPD) where baseline lung cancer risk is already elevated, and long-term antihypertensive therapy is planned.
• A patient who already experiences ACE inhibitor cough, which independently suggests elevated bradykinin accumulation.
• A patient with first-degree relatives with lung cancer who asks about modifiable risk factors and expresses a preference for the ARB class after reviewing the uncertainty.

These are situations where the clinical uncertainty tips the individualized benefit-risk calculation, not situations where switching is mandatory.

When to Stay on Lisinopril

Heart failure with reduced ejection fraction (HFrEF) is one area where the evidence base for ACE inhibitors is substantially deeper than for ARBs in specific subgroups. SOLVD-Treatment (N=2,569) demonstrated that enalapril reduced all-cause mortality by 16% (P<0.0001) in HFrEF patients [14]. The CONSENSUS trial showed a 40% reduction in one-year mortality with enalapril versus placebo in NYHA Class IV heart failure (P<0.002) [15]. These mortality benefits are large and replicated. Switching a stable HFrEF patient from an ACE inhibitor to an ARB solely on the basis of an unconfirmed observational cancer signal carries its own risk.

Monitoring Considerations

No specialized cancer screening protocol is currently recommended for ACE inhibitor users beyond standard-of-care lung cancer screening per USPSTF criteria: annual low-dose CT (LDCT) for adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or have quit within the past 15 years [16]. A patient on long-term lisinopril who meets USPSTF criteria should receive LDCT screening regardless of their antihypertensive regimen.

Confounding Factors That Complicate Interpretation

Smoking as a Confounder

Hypertension and smoking co-occur at higher rates than chance. Patients with uncontrolled hypertension may have more cardiovascular risk factors, including smoking, than age-matched ARB users. If residual smoking confounding persists even after statistical adjustment, the Azoulay HR of 1.14 could shrink to near 1.0. The UK Biobank analysis specifically addressed this and found the association disappeared [8].

Immortal Time Bias

Several of the observational studies, including earlier analyses, were vulnerable to immortal time bias: patients who filled multiple ACE inhibitor prescriptions were inherently "alive" for longer in the observation window, which can artifactually reduce their event rates or, if miscategorized, inflate them. Azoulay's group used time-conditional analysis methods to address this, but observational pharmacoepidemiology cannot fully eliminate it.

Indication Bias

Patients prescribed ARBs rather than ACE inhibitors in clinical practice are sometimes those who already had ACE inhibitor cough or a history of adverse reactions, meaning the ARB group may be systematically different in baseline lung health from the ACE inhibitor group. This selection effect could create a spurious protective ARB signal.

What Still Needs to Be Studied

A prospective randomized trial comparing long-term ACE inhibitor versus ARB use with cancer incidence as a co-primary endpoint would resolve the question. No such trial is currently underway in a powered form. The SPRINT trial (N=9,361) compared intensive versus standard blood pressure control and did not find significant cancer outcome differences by drug class, but it was not designed to address this question and ran for only 3.26 years median follow-up [17].

Biomarker studies measuring urinary bradykinin metabolites in long-term ACE inhibitor users correlated with lung biopsy findings could clarify whether the mechanistic pathway is active in humans at clinical doses. Such studies remain small and preliminary.